

Treatment (infusion)		Heart rate (bpm)	MAP (mmHg)	Systolic blood pressure (mmHg)	Diastolic blood pressure (mmHg)
(GIP(3-30)NH ₂ vs. saline)	Time (minutes)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)	Mean difference (95% CI)
Placebo	-25	-2.1 (-6.5 to 2.3)	-3.0 (-8.3 to 2.4)	-1.7 (-11.4 to 8.1)	-3.6 (-8.2 to 0.9)
	15	-5.5 (-11.3 to 0.2)	2.6 (-6.7 to 11.8)	2.7 (-11.0 to 16.3)	2.5 (-5.1 to 10.0)
	75	-5.0** (-8.7 to -1.4)	4.7 (-3.7 to 13.1)	5.3 (-6.7 to 17.3)	4.4 (-3.2 to 12.1)
	150	-3.3 (-8.4 to 1.8)	1.0 (-5.2 to 7.1)	2.2 (-8.5 to 12.8)	0.4 (-4.8 to 5.7)
	245	-1.4 (-4.3 to 1.6)	1.4 (-4.7 to 7.5)	4.2 (-7.0 to 15.4)	0.0 (-4.7 to 4.7)
Sitagliptin	-25	-2.6 (-6.9 to 1.6)	0.3 (-4.0 to 4.7)	-1.0 (-10.1 to 8.2)	1.0 (-2.8 to 4.7)
	15	-4.9** (-8.5 to -1.2)	2.7 (-2.7 to 8.0)	1.7 (-5.9 to 9.2)	3.2 (-2.2 to 8.5)
	75	-4.9** (-8.3 to -1.6)	4.8 (-2.9 to 12.5)	7.2 (-5.0 to 19.3)	3.7 (-2.6 to 9.9)
	150	-2.5 (-6.4 to 1.5)	5.4** (2.4 to 8.4)	8.0* (2.1 to 13.9)	4.1* (0.8 to 7.4)
	245	-0.7 (-4.7 to 3.3)	5.1* (0.5 to 9.7)	8.9 (-0.6 to 18.4)	3.2 (-0.2 to 6.5)

Supplementary Table 1. Changes in heart rate and blood pressure during GIP(3-30)NH₂ infusion compared to saline during placebo and sitagliptin treatment. Comparisons are made by two-way ANOVA with Tukey's correction for multiple comparisons and are presented as mean differences with 95% confidence intervals in parentheses. Asterisks indicate significance level: * $P < 0.05$ and ** $P < 0.005$. GIP, glucose-dependent insulinotropic polypeptide; bpm, beats per minute; MAP, mean arterial pressure; CI, confidence interval.